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lines through inhibition of Aurora kinase family
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Abstract
Background: Breast cancer is classified into three subtypes by the expression of biomarker receptors such as
hormone receptors and human epidermal growth factor receptor 2. Triple-negative breast cancer (TNBC) expresses
none of these receptors and has an aggressive phenotype with a poor prognosis, which is insensitive to the drugs
that target the hormone receptors and human epidermal growth factor receptor 2. It is, thus, required to develop
an effective therapeutic reagent to treat TNBC.
Results: The study using a panel of 19 breast cancer cell lines revealed that midostaurin, a multi-target protein
kinase inhibitor, suppresses preferentially the growth of TNBC cells comparing with non-TNBC cells. Clustering
analysis of the drug activity data for the panel of cancer cell lines predicted that midostaurin shares the target
with Aurora kinase inhibitors. Following studies indicated that midostaurin attenuates the phosphorylation reaction
mediated by Aurora kinase in the cells and directly inhibits this protein kinase in vitro, and that this reagent induces
apoptosis accompanying accumulation of 4N and 8N DNA cells in TNBC cells.
Conclusion: Midostaurin suppresses the proliferation of TNBC cells among the breast cancer cell lines presumably
through the inhibition of the Aurora kinase family. The precise study of midostaurin on cell growth will contribute
to the development of the drug for the treatment of TNBC.
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Background
The human genome encodes more than 500 protein
kinases, which are divided into two major groups recog-
nizing the hydroxyl side chains of serine/threonine and
tyrosine, respectively [1–3]. It is well known that the pro-
tein kinases are involved in various aspects of fundamental
cellular functions including growth and proliferation:
perturbations of protein kinases caused by mutation and
overexpression have been implicated in carcinogenesis
and its development, and aberrantly activated protein
kinases are regarded as potential therapeutic targets for
cancers [4]. For example, the screening for the inhibitors
against the constitutively activated tyrosine kinase BCR-
ABL, which is generated by chromosomal translocation
and gene fusion in chronic myeloid leukemia, identified
the small molecule inhibitor imatinib as a molecular-
targeted anticancer drug [5]. Midostaurin, also known as
PKC412, is a protein kinase inhibitor originally developed
against PKC, a serine/threonine protein kinase family [6].
It has later been shown that this compound inhibits not
only a series of serine/threonine protein kinases including
the PKC family but also tyrosine protein kinases [7]. FLT-3
(FMS-like tyrosine kinase-3) receptor kinase is one of the
targets of midostaurin, and its mutations are frequently
found in acute myeloid leukemia (AML), which result in
the constitutive activation of FLT-3 and induce cell prolif-
eration [8]. Thus, midostaurin has been developed as a
drug for the treatment of AML. Midostaurin, on the other
hand, is effective on AML and other cell lines derived from
solid tumors without aberration in FLT-3 [6, 9]. As midos-
taurin is a multi-target protein kinase inhibitor having a
broad inhibition spectrum [7], it is suggested that midos-
taurin shows its anti-cancer effect against the target other
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than FLT-3. Little is, however, known about the molecular
mechanism for the midostaurin as a multi-target anti-
cancer reagent.
Breast cancer is one of the most common malignancies
in women, nowadays, which is classified into the subtypes
according to the expression of biomarkers: the hormone
and growth factor receptors. They include the subtype
expressing human epidermal growth factor receptor 2
(HER2), the subtype expressing endocrine receptors such
as estrogen and progesterone receptors without expres-
sion of HER2 (ER+), and the subtype with none of these
receptors called triple-negative breast cancer (TNBC)
[10]. TNBC, highly overlapping with the basal-like
subgroup defined by microarray analysis [11], has an
aggressive phenotype with a relatively poor prognosis.
There is no specific drug for TNBC, although hormone
therapy is established for the treatment of ER+ breast can-
cer, and lapatinib, a small molecule inhibitor for human
epidermal growth factor receptor 2, is employed for HER2
breast cancer, which also inhibits epidermal growth factor
(EGF) receptor [10, 11]. It is, thus, required to develop an
effective drug to treat this breast cancer subtype.
We examined the effect of several protein kinase in-
hibitors on a panel of 19 breast cancer cell lines covering
these three subtypes, and found that midostaurin prefer-
entially suppresses cell growth of the TNBC cell lines.
The breast cancer cells do not express FLT-3 [12], and
thus it is of interest to identify the target of midostaurin
in the TNBC cell lines. On the other hand, the clustering
analysis of the drug activity data for a panel of cancer
cell lines has been widely used as a tool for the develop-
ment of anti-cancer drugs [13]. As drugs sharing the
target molecule(s) show similar growth inhibition pat-
terns among the cancer cell lines, it is possible to line up
the tested drug along with the compounds having
known targets [13]. The combination of the results of
midostaurin obtained herein and data of the previous
study [14] followed by the clustering analysis predicted
that midostaurin shares the target with Aurora kinase
inhibitors in breast cancer cell lines.
Aurora kinase is a family of serine/threonine protein
kinases consisting of three members of A, B, and C,
which have crucial roles for cell division by controlling
chromatid segregation and cytokinesis [15]. Aurora
kinases A and B are found in various tissues, but the
expression of Aurora kinase C is restricted in testis and
its overexpression has been reported in certain cancer
cells [15]. Dysregulation of Aurora kinases A and B has
been implicated in various cancers including AML [16]
and breast cancer [17], and thus Aurora kinases A and B
have been regarded to be possible targets of the cancer
therapy [15]. Therefore, the effect of midostaurin on
these Aurora kinases was studied in the breast cancer
cell lines.
Methods
Cell lines and culture conditions
Breast cancer cell lines used in this study were pur-
chased from American Type Culture Collection (ATCC,
Rockville, Maryland): ER+ includes HCC1428, MCF7,
and ZR-75-1; HER2 includes AU565, BT-474, HCC1419,
HCC1954, MDA-MB-453, SK-BR-3, and ZR-75-30;
TNBC includes BT-20, BT-549, HCC1806, HS578T,
MDA-MB-157, MDA-MB-231, MDA-MB-435S, MDA-
MB-436, and MDA-MB-468 [18–20]. The cells were
cultured under the conditions described in Additional
file 1 with fetal bovine serum (FBS) purchased from
Thermo Fisher Scientific (Waltham, Massachusetts).
Inhibitors
Midostaurin and lapatinib were purchased from LC
Laboratories (Woburn, Massachusetts). VX-680 was from
Symansis (Temecula, California). These inhibitors were dis-
solved in dimethyl sulfoxide (DMSO) at 10 mM and stored
at −20 °C until use. The final concentration of DMSO in
the culture medium and kinase assay mixture was 0.1 %.
Antibodies
Antibodies were obtained from commercial sources. Anti-
bodies against Aurora kinase A (#12100), p-Aurora A
Thr288/Aurora B Thr 232 (#2914), EGF receptor (EGFR)
(#2232), p-EGFR Tyr1068 (#3777), p-GSK-3β Ser9 (#9336),
p-Akt Ser473 (#4060), Akt (#4691), p-Erk Thr202/Thr204
(#4370), Erk 1/2 (#9102), poly(ADP-ribose) polymerase
(PARP) (#9542), PKC-α (#2056), PKC-δ (#2058), PKC-ε
(#2683), and p-Serine PKC substrates (#6967) were
purchased from Cell Signaling Technology (Beverly,
Massachusetts). Antibody against Aurora B (#ab45145)
was purchased from Abcam (Cambridge, UK). Antibody
against GSK-3β (#610201) was purchased from BD
Bioscience (San Jose, California). Antibodies against Histone
H3 (#sc-10809), PKC-βII (#sc-210) and γ-tubulin (#sc-
51715) were purchased from Santa Cruz Biotechnology
(Santa Cruz, California). Antibody against glyceraldehyde-3-
phosphate dehydrogenase (GAPDH) (#2275-pc-100) was
purchased from Trevigen (Gaithersburg, Maryland). The
antibody against p-Histone H3 Ser10 (#06-570) was
purchased from Millipore (Billerica, Massachusetts). Horse-
radish peroxidase-conjugated secondary antibodies against
rabbit and mouse IgG were purchased from Dako
(Glostrup, Denmark).
Cell viability assay
Cells grown on 96-well white culture plate at the density
of 4 × 103 cells/well were treated with each inhibitor for
72 h unless otherwise indicated. Cell viability was quan-
tified using Cell Titer-Glo assay kit (Promega, Madison,
Wisconsin), and the results were expressed as a ratio
relative to that of the control cells treated with DMSO.
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Western blot analysis
The cells with or without the treatment were subjected to
Western blot analysis as described [21] with minor
modifications. Cells were lysed in lysis buffer [20 mM
Tris–HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, 1 %
Triton X-100, 20 mM NaF, 1 mM Na3VO4, 0.1 % protease
inhibitor cocktail (Sigma-Aldrich, St. Louis, Missouri)].
Protein concentrations of cell lysates were measured with
DC protein assay kit (Bio-Rad, Hercules, California), and
equal amounts of the protein samples for each experiment
(1–20 μg) were separated by SDS–PAGE and transferred
to Immobilon P (Millipore). Blots were incubated with
respective primary and secondary antibodies at room
temperature for 1 h. Proteins were detected using chemi-
luminescent substrate (Pierce, Rockford, Illinois) accord-
ing to the manufacturer’s protocol and either LAS-4000
(Fujifilm, Tokyo, Japan) or CEPROS P2 (Fujifilm). The
experiments including Aurora kinases were carried out
after calibration by using GAPDH as an internal control.
Where indicated, the signals were semi-quantitated by
using Image J [22].
Clustering analysis of drug inhibition pattern
To find the target molecules responsible for the anti-
proliferative effect of midostaurin in breast cancer, a
hierarchal clustering method based on the drug efficacy
value was applied with minor modifications [13, 23].
Briefly, the GI50 values, the concentrations needed for
each of 74 drugs with known target(s) to inhibit prolifer-
ation by 50 % of 45 breast cancer cell lines [14], were
transformed using logarithm function to approximate
normal distribution. The viability of cell lines in the
presence of midostaurin, also having near normal distri-
bution, was then merged to the GI50 value dataset. Sub-
sequently, the cell lines were excluded, which miss the
values of more than half of the inhibitors. All of the rest-
ing values were transformed to z-score in each drug for
the normalization, and employed as the dataset in this
study. It is worth noting that the normalized GI50 values
and the viability data of midostaurin were obtained as
relative values, and are thus comparable among the
drugs. Pearson’s correlation distance was used for the
application of the clustering analysis as a dissimilarity
metric of both drugs and cell lines [24]. Since the dataset
still contains missing values, the correlation distances
were calculated by a pairwise manner. Calculation and
visualization of two-dimensional hierarchical clustering
were performed with R version 3.0.2 [25, 26].
In vitro kinase assay
GST-tagged Aurora kinase A and Aurora kinase B were
purchased from Carna Biosciences (Kobe, Japan). The kin-
ase activity of Aurora kinases A and B in the presence of
either midostaurin or VX-680 was evaluated using Aurora
Family Kinase Assay Kit (CycLex, Nagano, Japan) accord-
ing to manufacturer’s protocol.
Immunocytochemistry
Cells grown on coverslip were arrested by a single
thymidine block with 2 mM thymidine for 24 h as de-
scribed [27] with minor modifications, and subsequently
cultured in the thymidine-free medium in the presence
or absence of each inhibitor for 14 h. Resultant cells
were fixed with methanol for 3 min at −20 °C. Blocking
and incubation with antibodies were performed at room
temperature in phosphate-buffered saline containing 0.05 %
Tween 20 and 4 % bovine serum albumin. Cells were coun-
terstained with Hoechst 33342 (0.5 μg/ml), mounted using
FluoroSave reagent (Calbiochem, Darmstadt, Germany),
and observed under BZ-9000 (Keyence, Japan).
Cell cycle analysis
Cells were cultured with each inhibitor for various pe-
riods, harvested with trypsin, and fixed with 70 % ethanol
at −20 °C overnight. Thereafter, the cells were incubated
in phosphate-buffered saline containing 0.25 mg/ml
DNase-free RNase (Nippon Gene, Tokyo, Japan) at 37 °C
for 15 min. Subsequently, an equal volume of propidium
iodide solution (50 μg/ml) was added. Samples were
analyzed with FACS Verse (BD Biosciences, San Jose,
California).
Statistical analysis
Statistical analyses were performed with R version 3.0.2
[25, 26]. Numbers of the experiments, standard deviations
(s.d.), and p-values were indicated in each experiment.
Results
Anti-proliferative effect of midostaurin on breast cancer
cell lines
A panel of 19 cell lines, representing three subtypes of
human breast cancer, 3 of ER+, 7 of HER2, and 9 of
TNBC, were treated with different concentrations of mid-
ostaurin, and cell viability was measured (Additional file
2). The effect of midostaurin differed among the cell lines,
and thus the viability was compared at 1 μM (Fig. 1a), be-
cause the plasma concentrations of the drug in clinical
trial for AML have been reported to be a few μM [9]. The
TNBC cells except for one line were more sensitive to
midostaurin than non-TNBC subtypes such as ER+ and
HER2 cells (Fig. 1a): the mean viability values of TNBC
and non-TNBC cell lines were 0.53 and 0.91, respectively.
The difference between TNBC and non-TNBC subtypes
was shown by box plot and was statistically significant
(Fig. 1b). The effect of midostaurin on cell death was ex-
amined by measuring the cleavage of PARP, as a marker of
apoptosis (Fig. 2). In consistent with the result of cell via-
bility, midostaurin brought the cleavage of PARP in TNBC
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cell lines, BT-20 and MDA-MB-468, but the fragment was
not detected in non-TNBC cell lines, BT-474 and
HCC1419. These results indicate that midostaurin induces
apoptosis preferentially in TNBC cells. Midostaurin was
initially generated as a PKC inhibitor [6], and the
expression level of the PKC isoforms was evaluated in the
breast cancer cell lines by Western blot analysis. PKC iso-
forms were detected in the breast cancer cell lines such as
PKC-α and PKC-βII of the conventional PKC group as
well as PKC-δ and PKC-ε of the novel PKC group (Add-
itional file 3). Midostaurin suppressed the PKC-mediated
protein phosphorylation as judged by Western blot ana-
lysis using the p-Serine PKC substrates antibody in MDA-
MB-468 cell line (Additional file 4). The correlation of the
expression level of the PKC isoforms with the TNBC cell
lines was, however, not observed. On the other hand, it is
well known that TNBC cancer cells frequently express
EGF receptor although other two subtypes do not [28].
Therefore, the effect of midostaurin was examined on the
phosphorylation of EGF receptor and its downstream EGF
signaling mechanisms including Akt and Erk kinases.
While the treatment of midostaurin at 1 μM induced
apoptosis by 24 h as judged by the cleavage of PARP, no
significant suppression of the phosphorylation of EGFR
(p-EGFR Tyr1068), GSK-3β (p-GSK-3β Ser9), and Erk
(p-Erk Thr202/Thr204) was observed during the period
(Additional file 4). In addition, lapatinib, a potent inhibitor
of the EGF receptor kinase, did not suppress viability of
MDA-MB-468 cells, as described previously [29], or en-
hance the effect of midostaurin (data not shown). Namely,
these observations indicate that midostaurin does not
target EGF receptor in the TNBC cells.
Clustering analysis of inhibitors
To find the target molecule(s) of midostaurin responsible
for its anti-proliferative effect, the drug efficacy pattern of
midostaurin against the panel of cancer cell lines was
compared with that of the drugs having known targets by
clustering analysis. The dataset of drug sensitivity of 45
breast cancer cell lines against various known target [14]
were utilized as the reference data. The reference data lack
HS578T and MDA-MB-435S and contain 17 of the 19 cell
lines employed in this study, and were merged with the
drug sensitivity data of midostaurin of 17 cell lines, while
ZR-75-30 in Fig. 1a and other three cell lines in the refer-
ence data were excluded because of excess missing values.
The resulting data of 75 drugs, 74 drugs in the reference
data and midostaurin, and 41 cell lines were then applied
for clustering analysis as shown in Fig. 3. Gefitinib and
Fig. 1 Growth inhibition of breast cancer cell lines by midostaurin.
The 19 breast cancer cell lines were treated with 1 μM midostaurin
for 72 h, and cell viability was measured. a Cell viability shown as a
ratio relative to the control sample without treatment. Bars are 1 s.d.
of quintuple experiments. Breast cancer subtypes are indicated as
follows: gray, TNBC; light gray, HER2; white, ER+. b Box plot showing
relative viability according to breast cancer subtypes. TNBC vs.
non-TNBC, p = 0.00075 by Welch’s t-test
Fig. 2 Apoptosis induction by midostaurin. TNBC and non-TNBC cells indicated were treated with 1 μM midostaurin for various periods, and then
subjected to Western blot analysis using the antibody against PARP to detect its cleavage. GAPDH was employed as a control
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Fig. 3 Hierarchical clustering of drugs based on similarity of anti-proliferation effect profiles on breast cancer cell lines. Two-dimensional hierarchical
clustering was applied to growth inhibitory activity data of 76 anticancer drugs, including midostaurin, of a panel of breast cancer cell lines. The
sensitivity level against each drug in a single cell line relative to its mean value across all cell lines was depicted according to the color scale shown
at the upper left corner in the figure, and gray indicates missing values. Drugs with similar mechanisms of action tended to cluster together
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AG1478, for example, which are potent inhibitors of the
EGF receptor kinase [30], were classified into the same
cluster (Lines No. 46 and 47 from the top of the panel,
respectively). Doxorubicin, CPT-11, and topotecan, which
are potent inhibitors of the topoisomerases [14] were
classified into the same cluster (Lines No. 64 to 66 from
the top of the panel, respectively). These data are similar
to the previous report [14] confirming the validity of the
clustering analysis. Under these conditions, midostaurin
was found in the cluster with VX-680 and GSK1070916,
Aurora kinase inhibitors [14, 31]. These results suggest
that Aurora kinase is a candidate for the target, which is
responsible for the anti-proliferative effect of midostaurin
in the TNBC cell lines.
Effect of midostaurin on Aurora kinases
To determine the role of Aurora kinases in TNBC, the ex-
pression level of Aurora kinases A and B was examined in
the cancer cell lines (Fig. 4). Expression of Aurora kinases
A and B was detected among various cell lines, and was
generally high in the TNBC cell lines relative to the non-
TNBC cell lines. The phosphorylation of Aurora kinases
A and B at Thr288 and Thr232, respectively, as well as
that of Histone H3 at Ser10 was evaluated an indicator of
the Aurora kinase activity [32]. Notably, the phosphoryl-
ation of Histone H3 at Ser10, recognized by Aurora kinase
B [32], was high in most of the TNBC cell lines in agree-
ment with the expression level of Aurora kinases A and B.
The phosphorylation of Aurora kinases A and B was sig-
nificantly high in two TNBC cell lines, HCC1806 and
MDA-MB-468, but was weak in other cell lines. Thus, the
effect of midostaurin was examined on these phosphoryl-
ation reactions in the TNBC cell line of MDA-MB-468
(Fig. 5a). The midostaurin treatment significantly reduced
the Aurora kinase-mediated phosphorylation reactions in
the cell line. Although the effect was weaker than that of
VX-680, midostaurin at 1 μM attenuated the phosphoryl-
ation of Aurora kinases A and B as well as Histone H3. In
vitro kinase assay showed that midostaurin at 1 μM inhib-
ited the kinase activity of GST-tagged Aurora kinases A
and B by 16 and 34 %, respectively (Fig. 5b). Furthermore,
the negative correlation was observed between the phos-
phorylation level of Histone H3 Ser10 and cell viability
after the midostaurin treatment (Fig. 6a): Pearson’s correl-
ation coefficient was −0.51 (p = 0.021 by Pearson correl-
ation test). Most of the TNBC cell lines showed a high
level of phosphorylation of Histone H3 Ser10 with low cell
viability. The phosphorylation level of Histone H3 was
higher in TNBC cell lines than that in non-TNBC cell
lines (Fig. 6b). These results indicate that midostaurin dir-
ectly inhibits Aurora kinases A and B, and subsequently
reduces cell viability predominantly in the TNBC cells.
Effect of midostaurin on mitotic cells and cell cycle
progression
It has been reported that Aurora kinases are expressed
in M phase and the activity is required for the proper
mitotic progression [33]. Previous studies have reported
that the inhibition of Aurora kinase A suppresses spindle
organization [15], and that the inhibition of both Aurora
kinases A and B by VX-680 results in the accumulation
of 4N DNA cells followed by the induction of 8N DNA
cells and apoptosis [32]. To evaluate the effect of midos-
taurin on mitotic progression, the structure of cell nuclei
of the TNBC cell line, MDA-MB-468 was observed after
the midostaurin treatment (Fig. 7). Midostaurin, as well
as VX-680, suppressed the phosphorylation of Histone
H3 Ser10 in M phase cells, and induced defect of spindle
organization as judged by immunostaining [34]. Flow cy-
tometric analysis indicated that midostaurin accumulates
4N DNA cells regardless of the breast cancer subtypes
suggesting the induction of G2/M arrest (Fig. 8). Fur-
thermore, even 8N DNA cells were found in the TNBC
cell lines, BT-20 and MDA-MB-468, and less signifi-
cantly or not in non-TNBC cell lines. Sub-G1 fraction
was observed in the TNBC cell lines but not in non-
TNBC cell lines in consistent with the result of the
cleavage of PARP (Fig. 2). VX-680, in agreement with
the previous study, showed the results almost identical
to those of midostaurin [30]. Namely, midostaurin
showed the inhibitory effect on cell cycle progression of
the cancer cell lines employed as in the case of VX-680,
and induced apoptosis restrictively in the TNBC cells.
Discussion
In this study, it was revealed that midostaurin preferen-
tially suppresses proliferation of TNBC cells among the
breast cancer cell lines. Clustering analysis herein predicted
that midostaurin shares the target with Aurora kinase
inhibitors in the breast cancer cell lines. The Aurora kinase
Fig. 4 Western blot analysis of breast cancer cell lines. Cell lysates
from the 19 breast cancer cell lines were subjected to Western blot
analysis. Aurora kinases A and B, p-Aurora kinase A and B, and
Histone H3 and p-Histone H3 Ser10 were detected using respective
antibodies. The experiments were carried out after calibration by
using GAPDH as an internal control. Breast cancer subtypes are
indicated as follows: gray, TNBC; light gray, HER2; white, ER+
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family has three members, Aurora kinases A, B, and C,
and the inhibitors identified by the clustering analysis,
VX-680 and GSK1070916, are so-called pan-Aurora kinase
inhibitors, which suppress all Aurora kinases [31]. Among
the Aurora kinase family, Aurora kinases A and B are
expressed ubiquitously and have crucial roles for cell
division, whereas Aurora kinase C is restricted in testis and
is overexpressed in some tumors [15]. Therefore, we
concentrated our attention on Aurora kinases A and B in
this study. The following analysis indicated that midos-
taurin shows the properties quite similar to those of VX-
680: suppression of the phosphorylation reaction by Aur-
ora kinases in the TNBC cells, inhibition of the in vitro
kinase reaction of Aurora kinases A and B, and dysregula-
tion of spindle formation, and attenuation of cell cycle
progression. Aurora kinase inhibitors are regarded as
therapeutic reagents for various cancers [15, 31], and
midostaurin is known to inhibit multiple protein kinases
including Aurora kinases in comprehensive in vitro assay
[7]. Midostaurin was, however, shown for the first time to
suppress proliferation of the TNBC cells, at least, targeting
Aurora kinases. On the other hand, Akt, a serine/threonine
protein kinase family, has been proposed to be a target of
midostaurin for its anti-cancer effect [35]. It is less possible
that Akt is affected by midostaurin because this drug did
not attenuate the phosphorylation of GSK-3β by Akt,
whereas it immediately inhibited the reaction medicated
by PKC as indicated in this study. The results do not ne-
cessarily exclude the existence of another target molecule
of midostaurin, but it could be concluded that midostaurin
acts on the Aurora kinase pathway to inhibit the growth of
the TNBC cells.
Aurora kinases A and B play central roles in mitotic
process: Aurora kinase A is essential in maturation of
centromere and spindle assembly, and Aurora kinase B is
required for spindle assembly checkpoint function and in
cytokinesis process [15]. VX-680 has been employed as a
pan-Aurora kinase inhibitor to analyze the phenotypes by
the pharmacological inhibition of both Aurora kinases A
and B. Dual inhibition of Aurora kinases A and B induces
Fig. 5 Inhibition of Aurora kinases A and B by midostaurin. The effect of midostaurin on Aurora kinases A and B was examined comparing with
that of VX-680. a MDA-MB-468 cells were treated with midostaurin or VX-680 at indicated concentrations for 3 h, and then subjected to Western
blot analysis using the antibodies as in Fig. 4. b In vitro kinase activity of Aurora kinases A and B was measured in the presence of midostaurin or
VX-680 at indicated concentrations, and the results were shown as a ratio relative to the control sample in the absence of the inhibitor. Bars are
1 s.d. of duplicate experiments
r = -0.51
a b
Fig. 6 Association between phosphorylation status of Histone H3 Ser10 and viability of midostaurin treated cells in breast cancer cell lines. The
phosphorylation of Histone H3 Ser10 and Histone H3 in breast cancer cell lines was semi-quantified by densitometry after Western blot analysis.
The phosphorylation level is determined as a ratio of the value of the phosphorylation at Ser10 against that of the total protein of Histone H3
and indicated as p-Histone H3/Histone H3. The values are shown in as relative to MDA-MB-468 cell. a The association of the phosphorylation level
of Histone H3 Ser10 with cell viability after the midostaurin treatment. Pearson’s correlation coefficient: −0.51, p = 0.021 by Pearson correlation test.
b Box plot showing the phosphorylation level of Histone H3 Ser 10 among the breast cancer subtypes
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the phenotypes apparently identical to those of inactiva-
tion of Aurora kinase B [36]. Attenuation of Aurora kinase
A results in spindle defects, whereas inhibition of Aurora
kinase B blocks chromosomal alignment and, moreover,
overrides the spindle checkpoint. Therefore, the replica-
tion of the nuclear genome occurs without cell division,
and the cells show endoreplication such as elevated
nuclear content and polyploidy [36]. TNBC is generally
considered to be more aggressive with a higher prolifera-
tion activity than other breast cancer subtypes. Aurora
kinases are activated at M phase of cell cycle for the
normal mitotic process, and inhibition of these kinases
prevents cell cycle progression and leads to apoptosis
[36, 37]. It could be a reason that the TNBC cells have a
higher population in the midostaurin-sensitive phase than
other breast cancer subtypes. The TNBC cells, on the
other hand, frequently express EGF receptor, whereas
other two subtypes do not [11]. It has been reported that
EGF induces the gene expression of Aurora kinase A
through the nuclear translocation of EGF receptor with
STAT5 (signal transducer and activator of transcription 5)
followed by the recruitment of them to the promoter of
Aurora kinase A [38]. It seems thus possible that the
TNBC cells contain a high level of Aurora kinase A as one
of their malignant properties through the EGF-signaling
pathway, and that the resulting overexpression of Aurora
kinase A makes the TNBC cells sensitive to midostaurin.
On the other hand, overexpression of Aurora kinase C has
been found in some cancer cells [15], and thus it is neces-
sary to study the effect of midostaurin on the cancer cells
having Aurora kinase C. Recently, it has been reported
that VX-680 selectively kills the cells that overexpress
Myc [39], and the level of Myc is elevated in TNBC [40].
The precise mechanism of the synthetic lethal interaction
between VX-680 and Myc overexpression is not yet
known, but midostaurin may also affect the growth the
cells overexpressing Myc. Further studies are necessary to
elucidate the role of midostaurin in the preferential
growth inhibition to develop the drug as an anti-cancer
drug against TNBC.
Currently, midostaurin has been evaluated as the drug
for the treatment of AML by targeting FLT-3, which is
expressed exclusively in hematopoietic cells [12]. The
Fig. 7 Aberrant mitosis of midostaurin treated cell. MDA-MB-468 cells
were synchronized with the thymidine treatment, and subsequently
cultured in thymidine-free medium with the indicated inhibitor. Cells
were fixed, stained with Hoechst or each antibody, and observed
under fluorescence microscope. Nuclear condensation was used as a
marker of M phase cells
Fig. 8 Cell cycle analysis of midostaurin treated cells. TNBC and non-TNBC cells indicated were cultured in the presence and absence of either
1 μM midostaurin or 1 μM VX-680 for indicated periods and subjected to cell cycle analysis. The positions of sub G1, 2N, 4N, and 8N DNA are indi-
cated at the bottom
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previous clustering analysis of the drug activity data had
been carried out using various cancer cells of 60 cell
lines [13]. Here, we employed only breast cancer cell
lines, in which the effect against FLT-3 was excluded
from the analysis, and picked up Aurora kinases as the
candidate for the target of midostaurin in TNBC cells.
The results obtained in this study suggest that midos-
taurin shows its anti-cancer effect on AML by targeting
not only FLT-3 but also Aurora kinases, especially in
leukemia without aberration in FLT-3. This approach
employing restricted cancer cell lines may be useful to
identify the target molecule(s) of the multi-target protein
kinase inhibitors in different cancers.
Conclusions
Midostaurin has been developed as the drug for the treat-
ment of AML, which has constitutive active FLT-3. The
results obtained indicate that midostaurin preferentially
inhibits growth of the TNBC cell lines through inhibition
of the Aurora kinase family. It is plausible that midostaurin
has a potential to be a drug for the treatment of different
types of cancer by inhibiting respective target kinases.
Additional files
Additional file 1: Cell culture conditions. Cell lines employed in this
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p-Serine PKC substrates, and GAPDH were detected.
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